COXEN model picks the best drug for ovarian cancer

February 18, 2014

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

Because it has been so difficult to predict which ovarian cancers will respond to each of these three drugs, doctors have largely been forced to guess which will work best – and so in this study of four groups of 783 patients each, some were accidentally given what would turn out to be the best possible whereas others were given one of the two other, less good drugs. The model, called COXEN (CO-eXpression gENe analysis), sorts through the massive genetic data of thousands of samples to discover differences between tumors that responded and tumors that did not.

"The model allowed us to ask what would have been the right drug in each case, how could we have known from the tumor's genetics, and what difference it made," says Jennifer R. Diamond, MD, CU Cancer Center investigator and medical oncologist at the University of Colorado Hospital.

When COXEN looked back through this registry of advanced ovarian cancer, it first sorted tumors into those that had responded and those that had not responded to each drug ("what would have been the right drug in each case"). It then pinpointed genetic signatures of tumors that responded to each drug ("how could we have known from the tumor genetics"). And the study finally showed that patients who had been serendipitously given the drug that the COXEN model would have picked for them lived 21 months longer than the average patient with advanced ovarian cancer.

"We have traditionally considered site-specific cancer to be homogenous – one ovarian cancer is like the next ovarian cancer. But we are increasingly learning that isn't the case at all. The COXEN model allows us to identify the heterogeneity within the disease. It lets us see why some respond and others don't," Diamond says.

Diamond is also quick to point out that while the current study shows that COXEN could have been used to predict the most useful drug in many of these cases of advanced ovarian cancer, the actual use of the will be possible only after validation with a prospective clinical trial. In fact, a similar strategy led to similar results in , and a prospective clinical trial of COXEN in bladder cancer is underway at the CU Cancer Center and elsewhere.

"This study supports the idea that we could test ovarian cancer tumors and say they're more likely to respond to one or the other drugs," Diamond says.

Explore further: Drug delivery system successfully treats deadly ovarian cancer in mice

Related Stories

Biomarkers predict time to ovarian cancer recurrence

August 15, 2013

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...

Drug can delay ovarian cancer relapses: study

June 1, 2013

A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.

New ovarian cancer treatment succeeds in the lab

October 17, 2013

In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a ...

New drug extends life in women with advanced ovarian cancer

November 5, 2013

Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National ...

Recommended for you

Cancer hijacks natural cell process to survive

June 26, 2017

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

Targeted drug shows promise in rare advanced kidney cancer

June 23, 2017

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.